Last reviewed · How we verify
High Dose Colistin
High Dose Colistin is a Polymyxin antibiotic Small molecule drug developed by King Saud Medical City. It is currently FDA-approved for Multidrug-resistant gram-negative bacterial infections (Pseudomonas aeruginosa, Acinetobacter baumannii), Hospital-acquired pneumonia caused by resistant gram-negative organisms, Bloodstream infections caused by multidrug-resistant gram-negative bacteria. Also known as: colistin.
Colistin is a polymyxin antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides and causing leakage of cellular contents.
Colistin is a polymyxin antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides and causing leakage of cellular contents. Used for Multidrug-resistant gram-negative bacterial infections (Pseudomonas aeruginosa, Acinetobacter baumannii), Hospital-acquired pneumonia caused by resistant gram-negative organisms, Bloodstream infections caused by multidrug-resistant gram-negative bacteria.
At a glance
| Generic name | High Dose Colistin |
|---|---|
| Also known as | colistin |
| Sponsor | King Saud Medical City |
| Drug class | Polymyxin antibiotic |
| Target | Bacterial lipopolysaccharide (LPS) and outer membrane |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Colistin acts as a cationic antimicrobial peptide that interacts with the outer membrane of gram-negative bacteria, particularly lipopolysaccharides (LPS), leading to membrane destabilization and cell death. High-dose formulations are used to achieve adequate concentrations for treating serious infections caused by multidrug-resistant gram-negative organisms, especially Pseudomonas aeruginosa and Acinetobacter baumannii. The drug is typically reserved for infections resistant to other antibiotics due to its nephrotoxicity and neurotoxicity profile.
Approved indications
- Multidrug-resistant gram-negative bacterial infections (Pseudomonas aeruginosa, Acinetobacter baumannii)
- Hospital-acquired pneumonia caused by resistant gram-negative organisms
- Bloodstream infections caused by multidrug-resistant gram-negative bacteria
Common side effects
- Nephrotoxicity (acute kidney injury)
- Neurotoxicity (paresthesias, dizziness, vertigo)
- Neuromuscular blockade
- Fever
- Injection site reactions
Key clinical trials
- Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)
- Colistin Dosage Prsonalization Approach
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
- Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy (PHASE2)
- Safety and Efficacy Study of High Dose Colistin (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High Dose Colistin CI brief — competitive landscape report
- High Dose Colistin updates RSS · CI watch RSS
- King Saud Medical City portfolio CI
Frequently asked questions about High Dose Colistin
What is High Dose Colistin?
How does High Dose Colistin work?
What is High Dose Colistin used for?
Who makes High Dose Colistin?
Is High Dose Colistin also known as anything else?
What drug class is High Dose Colistin in?
What development phase is High Dose Colistin in?
What are the side effects of High Dose Colistin?
What does High Dose Colistin target?
Related
- Drug class: All Polymyxin antibiotic drugs
- Target: All drugs targeting Bacterial lipopolysaccharide (LPS) and outer membrane
- Manufacturer: King Saud Medical City — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Multidrug-resistant gram-negative bacterial infections (Pseudomonas aeruginosa, Acinetobacter baumannii)
- Indication: Drugs for Hospital-acquired pneumonia caused by resistant gram-negative organisms
- Indication: Drugs for Bloodstream infections caused by multidrug-resistant gram-negative bacteria
- Also known as: colistin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing